SCIB (9237)
- 0.125
- 0.0000.00%
9237 SCIB
First Patient Enrolled in New Study Assessing Early Prediction of Flares in Atopic Dermatitis by Castle Biosciences in Collaboration With SciBase
Sarawak Consolidated Ind Malaysia 1st-Quarter 2026 Earnings Summary Table
SCIB: Quarterly rpt on consolidated results for the financial period ended 31/03/2026
SciBase Announces That the Board of Directors Has Resolved on the Record Date for the Reverse Share Split
SciBase Wins US FDA Nod for Skin Cancer Detection Device Label Expansion
SCIB: Consolidated results for the financial period ended 31/12/2025
Sarawak Consolidated Unit to Undertake Real Estate Project
SciBase Expands Its Intellectual Property Portfolio to Include the Analysis of the Epithelial Skin Barrier With New European Patent
SCIB Delivers RM46.19 Million Revenue in Q5 FPE2025
SCIB: Consolidated results for the financial period ended 30/09/2025
SciBase, Castle Biosciences Expand License Deal, Secures SEK20 Million Loan
SciBase Plans Warrant Buyback; Mulls SEK83 Million Rights Issue
Sarawak Consolidated Gets More Time to Hold Annual Meeting
Sarawak Consolidated to Sell Entire Stake in SCIB Concrete for MYR113 Million; Shares Rally 24%
Sarawak Consolidated Industries Changes Financial Year End to Dec. 31
Nevisense Used in Fundamental Skin Barrier Research on Atopic Dermatitis
SciBase Lands Point-of-care Platform Order Under Clinical Study Partnership
SciBase Receives Initial Order for Clinical Study From Castle Biosciences
Main Owners Strengthen Their Position in SciBase
Sarawak Consolidated Industries Berhad Full Year 2025 Earnings: RM0.003 Loss per Share (Vs RM0.007 Profit in FY 2024)